<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1735">
  <stage>Registered</stage>
  <submitdate>8/10/2007</submitdate>
  <approvaldate>8/10/2007</approvaldate>
  <nctid>NCT00553267</nctid>
  <trial_identification>
    <studytitle>Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension</studytitle>
    <scientifictitle>An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EUDRACT 2007-002421-68</secondaryid>
    <secondaryid>1235.6</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - fixed dose combination of telmisartan+amlodipine
Treatment: drugs - amlodipine

Treatment: drugs: fixed dose combination of telmisartan+amlodipine


Treatment: drugs: amlodipine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Trough Seated Diastolic Blood Pressure - Change from baseline to the end of study in trough DBP</outcome>
      <timepoint>Baseline and end of study (8 weeks or last value on treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Trough Seated Systolic Blood Pressure - Change from baseline to the end of study in trough SBP</outcome>
      <timepoint>Baseline and end of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated Diastolic Blood Pressure Control (Defined as &lt; 90mmHg) - The number of patients who reach the target DBP of &lt;90mmHg</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated Diastolic Blood Pressure &lt;80 mmHg - The number of patients who reach the target DBP of &lt;80mmHg</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated DBP Response - The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated SBP Control - The number of patients who reach the target SBP of &lt;140mmHg</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated SBP Response - The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Seated BP Normality Classes - The number of patients who reach predefined BP categories</outcome>
      <timepoint>End of study (8 weeks or last value on treatment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oedema Incidence Rate - The number of patients who experienced at least one case of oedema or worsening of oedema for the first time (expressed as number of patients/100 patient-years)</outcome>
      <timepoint>During randomised treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral Oedema Incidence Rate - The number of cases of peripheral oedema (expressed as number of cases/100 patient-years)</outcome>
      <timepoint>During randomised treatment period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  diagnosis of essential hypertension and blood pressure not adequately controlled
             before informed consent (inadequate control defined as seated diastolic blood pressure
             (DBP) &gt;= 95 mmHg if on existing antihypertensive treatment or seated DBP &gt;= 100 mmHg
             if treatment-naïve).

          -  failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond
             defined as seated DBP &gt;= 90 mmHg.)

          -  able to stop any current antihypertensive therapy without unacceptable risk to the
             patient.

          -  willing and able to provide written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  pregnancy, breast-feeding, unwilling to use effective contraception (if female of
             child-bearing potential).

          -  known or suspected secondary hypertension.

          -  mean seated systolic blood pressure (SBP) &gt;=200 mmHg and/or mean seated DBP &gt;= 120
             mmHg during run-in treatment or mean seated SBP &gt;= 180 mmHg and/or mean seated DBP &gt;=
             120 mmHg at the randomisation visit or at any time during randomised treatment.

          -  any clinically significant hepatic impairment or severe renal impairment bilateral
             renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal
             transplant.

          -  clinically relevant hyperkalaemia.

          -  uncorrected volume or sodium depletion.

          -  primary aldosteronism.

          -  hereditary fructose or lactose intolerance.

          -  symptomatic congestive heart failure.

          -  patients who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or ARBs.

          -  history of drug or alcohol dependency within the six months prior to signing consent.

          -  concurrent participation in another clinical trial or any investigational therapy
             within thirty days prior to signing consent.

          -  hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
             aortic or mitral valve.

          -  known allergic hypersensitivity to any component of the formulations under
             investigation. (Includes known hypersensitivity to telmisartan or other ARBs or
             amlodipine or other dihydropyridine CCBs.)

          -  non-compliance with study medication (defined as less than 80% or more than 120%)
             during the open-label run-in treatment period.

          -  current treatment with any antihypertensive agents, whether or not prescribed for this
             indication, that cannot be safely stopped (investigator¿s decision) by the start of
             the run-in period.

          -  chronic administration of any medication known to affect blood pressure, other than
             the trial medication.

          -  any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of telmisartan and
             amlodipine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>947</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>1235.6.61003 Boehringer Ingelheim Investigational Site - Gosford</hospital>
    <hospital>1235.6.61004 Boehringer Ingelheim Investigational Site - Liverpool</hospital>
    <hospital>1235.6.61002 Boehringer Ingelheim Investigational Site - Kippa-Ring</hospital>
    <hospital>1235.6.61001 Boehringer Ingelheim Investigational Site - Milton</hospital>
    <hospital>1235.6.61005 Boehringer Ingelheim Investigational Site - Elizabeth Vale</hospital>
    <postcode> - Gosford</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Kippa-Ring</postcode>
    <postcode> - Milton</postcode>
    <postcode> - Elizabeth Vale</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Eggenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Hainburg a.d. Donau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Hartberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Bourgas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Benatky nad Jizerou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pribram</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Slany</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Strakonice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Birr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Carrigtwohill</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Enniscorthy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Gorey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Mallow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>New Ross</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Broni (pv)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Coppito (AQ)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otahuhu, Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Dolny Kubin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kralovsky Chmlec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Liptovsky Mikulas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Povazska Bystrica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trencin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Vrable</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jerez de la Frontera (Cádiz)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>L'Hospitalet de Llobregat (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santa Coloma de Gramanet</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Gordola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Erzurum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lvov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zaporozhye</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bexhill</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Burbage, Hinkley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chestfield, Whitstable</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chorley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edgbaston, Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Ely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Fowey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Penzance</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Reading</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Saltash</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>St Stephen, St Austell</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Whitstable</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this trial is to demonstrate that the fixed dose combination of
      telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan
      80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks
      compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks
      treatment with A10.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00553267</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>